B6-hIL6ST Mouse
Product Name
B6-hIL6ST Mouse
Product ID
C001786
Strain Name
C57BL/6NCya-Il6sttm1(hIL6ST)/Cya
Backgroud
C57BL/6NCya
When using this mouse strain in a publication, please cite “B6-hIL6ST Mouse (Catalog C001786) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
Gene Name
Gene Alias
CD130, GP130, HIES4, IMD94, STWS2, CDW130, HIES4A, HIES4B, IL-6RB, sGP130
NCBI ID
Chromosome
Chr 5
MGI ID
Datasheet
Strain Description
The IL6ST gene, also known as gp130, encodes a crucial signal-transducing protein that is part of the receptor complex for a wide range of cytokines, including Interleukin-6 (IL-6), leukemia inhibitory factor (LIF), ciliary neurotrophic factor (CNTF), and oncostatin M (OSM) [1]. This protein is ubiquitously expressed across various cellular tissues, including but not limited to the brain, heart, thymus, spleen, kidney, lung, liver, and endometrial tissues, playing critical roles in mediating signals that regulate immune response, hematopoiesis, pain control, bone metabolism, and embryonic development. Its function involves homodimerization upon cytokine binding to initiate intracellular signaling pathways like JAK-MAPK and JAK-STAT3, thereby influencing cell proliferation, differentiation, and survival [2]. Dysregulation or mutations in IL6ST are associated with several diseases, notably various forms of Hyper-IgE Syndrome (HIES), particularly Hyper-IgE recurrent infection syndrome type 4 (autosomal recessive and dominant forms), as well as playing a role in conditions like rheumatoid arthritis, multiple sclerosis, Crohn's disease, inflammatory bowel disease, breast cancer, and endometriosis [3-4].
The B6-hIL6ST mouse is a humanized model constructed by replacing the endogenous partial extracellular domain of the mouse Il6st gene with the human IL6ST partial extracellular domain. The murine signal peptide, transmembrane, and cytoplasmic domains are preserved. B6-hIL6ST mice can be used for research into the pathogenesis of inflammatory and autoimmune diseases, as well as certain tumors, and for the screening, development, and safety evaluation of IL6ST-targeted drugs.
Reference
Jones SA, Jenkins BJ. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat Rev Immunol. 2018 Dec;18(12):773-789.
Béziat V, Tavernier SJ, Chen YH, et al. Dominant-negative mutations in human IL6ST underlie hyper-IgE syndrome. J Exp Med. 2020 Jun 1;217(6):e20191804.
Gardner S, Jin Y, Fyfe PK, Voisin TB, Bellón JS, Pohler E, Piehler J, Moraga I, Bubeck D. Structural insights into IL-11-mediated signalling and human IL6ST variant-associated immunodeficiency. Nat Commun. 2024 Mar 7;15(1):2071.
Martínez-Pérez C, Kay C, Meehan J, Gray M, Dixon JM, Turnbull AK. The IL6-like Cytokine Family: Role and Biomarker Potential in Breast Cancer. J Pers Med. 2021 Oct 24;11(11):1073.
Strain Strategy
The mouse Il6st endogenous partial extracellular domain will be replaced with the human IL6ST partial extracellular domain. The murine signal peptide, transmembrane, and cytoplasmic domain will be preserved.
Figure 1. Gene editing strategy of B6-hIL6ST Mice.
Application Area
IL6ST-targeted drug screening, development, and evaluation;
Research on the pathological mechanisms and therapeutic approaches of inflammatory and autoimmune diseases;
Research on the pathological mechanisms and therapeutic approaches of certain tumors.
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.